Jiangxi maternal and child health hospital

Nanchang, Jiangxi 330006

3 studies enrolling now · 7 studies all time

What they study most

Breast Adenocarcinoma, Endometrial Cancer, Endometrial Hyperplasia, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Fallopian Tube Cancer, HER2-positive Advanced Solid Tumor, High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Mesothelioma, Non-small Cell Lung Cancer, Platinum Sensitive Ovarian Cancer (PSOC)

Studies at this site

• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) — Recruiting now
• A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer — Recruiting now
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors — Recruiting now
• Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months — Withdrawn before enrolling
• Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] — Completed
• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids — Stopped early
• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) — Stopped early